Literature DB >> 27597269

Predictive Modeling of Tacrolimus Dose Requirement Based on High-Throughput Genetic Screening.

C Damon1, M Luck1,2, L Toullec3, I Etienne4, M Buchler5, B Hurault de Ligny6, G Choukroun7, A Thierry8, C Vigneau9, B Moulin10, A-E Heng11, J-F Subra12, C Legendre13, A Monnot1, A Yartseva1, M Bateson1, P Laurent-Puig2,3,14, D Anglicheau13, P Beaune2,3,14, M A Loriot2,3,14, E Thervet2,15, N Pallet2,3,14,15.   

Abstract

Any biochemical reaction underlying drug metabolism depends on individual gene-drug interactions and on groups of genes interacting together. Based on a high-throughput genetic approach, we sought to identify a set of covariant single-nucleotide polymorphisms predictive of interindividual tacrolimus (Tac) dose requirement variability. Tac blood concentrations (Tac C0 ) of 229 kidney transplant recipients were repeatedly monitored after transplantation over 3 mo. Given the high dimension of the genomic data in comparison to the low number of observations and the high multicolinearity among the variables (gene variants), we developed an original predictive approach that integrates an ensemble variable-selection strategy to reinforce the stability of the variable-selection process and multivariate modeling. Our predictive models explained up to 70% of total variability in Tac C0 per dose with a maximum of 44 gene variants (p-value <0.001 with a permutation test). These models included molecular networks of drug metabolism with oxidoreductase activities and the multidrug-resistant ABCC8 transporter, which was found in the most stringent model. Finally, we identified an intronic variant of the gene encoding SLC28A3, a drug transporter, as a key gene involved in Tac metabolism, and we confirmed it in an independent validation cohort.
© 2016 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  clinical research/practice; genetics; genomics; immunosuppression/immune modulation; immunosuppressive regimens; pharmacology; translational research/science

Mesh:

Substances:

Year:  2016        PMID: 27597269     DOI: 10.1111/ajt.14040

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  5 in total

1.  Genome-wide association study identifies the common variants in CYP3A4 and CYP3A5 responsible for variation in tacrolimus trough concentration in Caucasian kidney transplant recipients.

Authors:  W S Oetting; B Wu; D P Schladt; W Guan; R P Remmel; R B Mannon; A J Matas; A K Israni; P A Jacobson
Journal:  Pharmacogenomics J       Date:  2017-11-21       Impact factor: 3.550

2.  Attempted validation of 44 reported SNPs associated with tacrolimus troughs in a cohort of kidney allograft recipients.

Authors:  William S Oetting; Baolin Wu; David P Schladt; Weihua Guan; Rory P Remmel; Casey Dorr; Roslyn B Mannon; Arthur J Matas; Ajay K Israni; Pamala A Jacobson
Journal:  Pharmacogenomics       Date:  2018-01-10       Impact factor: 2.533

Review 3.  Pharmacogenetics of Membrane Transporters of Tacrolimus in Solid Organ Transplantation.

Authors:  Camille Tron; Florian Lemaitre; Céline Verstuyft; Antoine Petitcollin; Marie-Clémence Verdier; Eric Bellissant
Journal:  Clin Pharmacokinet       Date:  2019-05       Impact factor: 6.447

4.  A Novel, Dose-Adjusted Tacrolimus Trough-Concentration Model for Predicting and Estimating Variance After Kidney Transplantation.

Authors:  Janet Kim; Sam Wilson; Nasrullah A Undre; Fei Shi; Rita M Kristy; Jason J Schwartz
Journal:  Drugs R D       Date:  2019-06

5.  The influence of recipient SLCO1B1 rs2291075 polymorphism on tacrolimus dose-corrected trough concentration in the early period after liver transplantation.

Authors:  Yi Wu; Fang Fang; Zhaowen Wang; Peihao Wen; Junwei Fan
Journal:  Eur J Clin Pharmacol       Date:  2021-01-02       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.